Accelerating COVID-19 R&D work-flows with microfluidic immunoassays

11 Feb 2022

In this white paper, Gyros Protein Technologies illustrates the contribution of automated flow-through microfluidic immunoassays using Gyrolab system in generating reliable data for applications in public health and the development of vaccines and antibody-based treatments.

Links

Tags